Back
Top 0.1%
11.8%
#1
11.0%
Top 61%
9.0%
#1
6.4%
Top 38%
6.4%
Top 0.2%
6.4%
Top 0.8%
4.2%
Top 1%
3.9%
Top 12%
3.9%
Top 42%
3.1%
Top 0.6%
2.8%
Top 0.2%
2.8%
Top 5%
1.9%
Top 17%
1.3%
Top 23%
1.2%
Top 14%
1.2%
Top 54%
1.0%
Top 2%
1.0%
Top 23%
0.7%
Top 34%
0.7%
Top 18%
0.7%
Top 6%
0.7%
Safety and efficacy of rapamycin on healthspan metrics after one year: PEARL Trial Results
2024-08-22
geriatric medicine
Title + abstract only
View on medRxiv
Show abstract
BackgroundLow-dose rapamycin promotes longevity in mice, but clinical safety and longevity data effects in humans remain limited. ObjectivesEvaluate the long-term safety of intermittent low-dose rapamycin in a healthy, normative-aging human cohort. DesignThis decentralized double-blinded, randomized, placebo-controlled trial (NCT04488601, registered 2020-07-28) was performed over 48 weeks. Participants received placebo, 5mg or 10mg compounded rapamycin (equivalent to 1.43mg or 2.86mg of generi...
Predicted journal destinations
1
Aging Cell
21 training papers
2
GeroScience
22 training papers
3
PLOS ONE
1737 training papers
4
The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences
15 training papers
5
Scientific Reports
701 training papers
6
The Journals of Gerontology: Series A
19 training papers
7
Age and Ageing
27 training papers
8
Nutrients
43 training papers
9
eLife
262 training papers
10
BMJ Open
553 training papers
11
BMC Geriatrics
15 training papers
12
Aging
18 training papers
13
Alzheimer's & Dementia
84 training papers
14
JAMA Network Open
125 training papers
15
BMC Medicine
155 training papers
16
PLOS Medicine
95 training papers
17
Nature Communications
483 training papers
18
The Journal of Clinical Endocrinology & Metabolism
26 training papers
19
Cureus
64 training papers
20
PLOS Global Public Health
287 training papers
21
Nature Medicine
88 training papers
22
eClinicalMedicine
55 training papers